Conatus Pharmaceuticals Inc., a biotechnology company, announced the appointment of William R. LaRue as an additional independent member to the Conatus board of directors.Staff Writer | San Diego, Ca., USA | Wednesday February 8, 2017 6:39AM ET
Conatus adds William R. LaRue to board
Mr. LaRue also will serve as Chair of the Audit Committee.
Mr. LaRue joined Cadence Pharmaceuticals, Inc., a biopharmaceutical company, as Senior Vice President and Chief Financial Officer in June 2006, and expanded his role to serve as Assistant Secretary at Cadence in April 2007, serving in both capacities until the company's acquisition by Mallinckrodt plc in March 2014.
During his tenure, Cadence raised over $375 million in public and private equity and senior debt, including an IPO in October 2006 as the company transitioned from a development stage to a commercial stage company.
Prior to joining Cadence, Mr. LaRue served as the Senior Vice President and Chief Financial Officer of CancerVax Corporation, a biotechnology company, from 2001 until its merger with Micromet, Inc. in May 2006.
He served from 2000 to 2001 as the Executive Vice President and Chief Financial Officer of eHelp Corporation, a provider of user assistance software; from 1997 to 2000 as the Vice President and Treasurer of Safeskin Corporation, a medical device company; and from 1993 to 1997 as the Treasurer of GDE Systems, Inc., a high technology electronic systems company.
Mr. LaRue currently serves as a member of the Board of Directors and Chair of the Audit Committee of Tracon Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, and as a member of the Board of Directors and Chair of Audit Committee of Applied Proteomics, Inc., a private, venture-backed, molecular diagnostics company.
He previously served on the boards of directors of Cadence Pharmaceuticals, Inc. and Neurelis, Inc., a specialty pharmaceutical company.
Mr. LaRue received a B.S. in business administration and an M.B.A. from the University of Southern California.